3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Lung Neoplasms
8
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
3
Brain Neoplasms
2
ALK-positive Advanced NSCLC
2
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Ependymoma
1
Disease Progression
1
Carcinoma, Squamous Cell
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Large Cell
1
Breast Neoplasms
1
Adenocarcinoma
1
ALK+ Advanced NSCLC
1
Interventions
Cisplatin
76
Radiotherapy
44
pembrolizumab
39
Cetuximab
38
Paclitaxel
34
Carboplatin
33
Docetaxel
30
Fluorouracil
25
Radiotherapy, Intensity-Modulated
22
Nivolumab
18
Drug Therapy
14
Radiation
12
Erlotinib Hydrochloride
9
cemiplimab
8
Magnetic Resonance Spectroscopy
8
130-nm albumin-bound paclitaxel
8
durvalumab
7
atezolizumab
7
Cyclophosphamide
7
Afatinib
7
Surgical Procedures, Operative
6
Panitumumab
6
Leucovorin
6
Chemoradiotherapy
6
fludarabine
5
aldesleukin
5
Radiosurgery
5
Oxaliplatin
5
Methotrexate
5
Gemcitabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Squamous Cell
×
brigatinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA